Evidence map›Paper›PMID 12370273›Full record

ArticleThe Journal of clinical investigation2002

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.

Hong Xiao, Peter Heeringa, Peiqi Hu, Zhi Liu, Minglang Zhao, Yasuaki Aratani, Nobuyo Maeda, Ronald J Falk, J Charles Jennette

Registry-linked trialAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00261118 (Phase 3), which is not on this map. Cited by 398 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
398citing papers in PubMed, 3 pooled it
36.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00261118 phase2 / phase3completednot on this mapstarted 2004, after this paper: background citation

Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis

TypeinterventionalSponsorRoyal Liverpool University HospitalRan2004 to 2009Enrolled24ConditionsUlcerative ColitisArmsRituximab
3 · Its place in the literature

Who cites it

398 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,002 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Role of therapeutic plasmapheresis in ANCA-associated vasculitis.Pediatric nephrology (Berlin, Germany) · 2016
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Nephrin autoimmunity: signal, noise, and a path to clarity.The Journal of clinical investigation · 2026
    Article
  12. Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

338 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Hong XiaoDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill,Chapel Hill, North Carolina 27599, USA.
Peter Heeringa
Peiqi Hu
Zhi Liu
Minglang Zhao
Yasuaki Aratani
Nobuyo Maeda
Ronald J Falk
J Charles Jennette
University of North Carolina at Chapel Hill · USMaastricht University · NLYokohama City University · JP

Funding

Translation of Knowledge on the Pathogenesis of ANCA Disease into NovelP01DK058335 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NACHMAN, PATRICK H · 2000 to 2019
$25.9M
APOLIPOPROTEIN GENES AND ATHEROGENESIS IN ANIMALSR37HL042630 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MAEDA, NOBUYO · 1998 to 2007
$3.4M
NHLBI NIH HHS R37 HL042630NIDDK NIH HHS DK58335NIDDK NIH HHS P01 DK058335
6 · The paper itself

Abstract

Antineutrophil cytoplasmic autoantibodies (ANCAs) are identified in the circulation of approximately 80% of patients with pauci-immune necrotizing and crescentic glomerulonephritis and systemic small vessel vasculitis, such as microscopic polyangiitis and Wegener granulomatosis. The most common antigen target for ANCAs is myeloperoxidase (MPO), which is found in neutrophils and monocytes. We report definitive experimental animal evidence that ANCAs are pathogenic. MPO knockout (Mpo(-/-)) mice were immunized with mouse MPO. Splenocytes from these mice or from control mice were injected intravenously into recombinase-activating gene-2-deficient (Rag2(-/-)) mice, which lack functioning B lymphocytes and T lymphocytes. All mice that received splenocytes developed mild to moderate glomerular immune deposits, but only mice that received 1 x 10(8) or 5 x 10(7) anti-MPO splenocytes developed severe necrotizing and crescentic glomerulonephritis, granulomatous inflammation, and systemic necrotizing vasculitis, including necrotizing arteritis and hemorrhagic pulmonary capillaritis. To test the pathogenic potential of antibodies alone, purified anti-MPO IgG or control IgG was injected intravenously into Rag2(-/-) mice and wild-type mice. Mice that received anti-MPO IgG but not mice that received control IgG developed focal necrotizing and crescentic glomerulonephritis with a paucity of glomerular Ig deposition. Thus, anti-MPO IgG alone was able to cause pauci-immune glomerular necrosis and crescent formation in the absence of functional T or B lymphocytes in Rag2(-/-) mice and in the presence of an intact immune system in wild-type C57BL/6J mice. This animal model offers strong support for a direct pathogenic role for ANCA IgG in human glomerulonephritis and vasculitis.

Indexed as

Adoptive TransferAnimalsAntibodies, Antineutrophil CytoplasmicCell LineDNA-Binding ProteinsFemaleGlomerulonephritisImmunization, PassiveImmunoglobulin GMaleMiceMice, Inbred C57BLNeutrophil ActivationPeroxidaseSerum Albumin, BovineVasculitisAntibodies, Antineutrophil CytoplasmicDNA-Binding ProteinsImmunoglobulin GPeroxidaseRag2 protein, mouseSerum Albumin, BovineV(D)J recombination activating protein 2

Identifiers

PMID12370273
PMCPMC151154
OpenAlexW2141225393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.